Related Experiment Video
Updated: May 15, 2025
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
Engineering CD5-targeting CAR-NK cells from peripheral blood for the treatment of CD5-positive hematological
Haolong Lin1,2, Lingfeng Zhang1,2, Tong Ge1,2
1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, P. R. China.
Background:
The therapeutic application of chimeric antigen receptor (CAR) T cells in T-cell malignancies faces substantial limitations owing to fratricide and potential T cell aplasia, primarily attributed to the shared expression of target antigens, such as CD5, between normal and malignant T cells. Although natural killer (NK) cell-based immunotherapy is a promising alternative approach, its efficacy in treating hematologic malignancies remains to be fully elucidated.
Methods:
CD5-targeted CAR-modified primary NK cells, T cells and NK92 cell lines were generated and comprehensively evaluated for their anti-tumor efficacy through in vitro cytotoxicity assays and xenograft mouse models. Furthermore, preliminary investigation of the herpes simplex virus-1 thymidine kinase (HSV-TK) suicide switch system in CAR-NK cells were conducted using ganciclovir (GCV) as the activating agent.
Results:
CAR-NK cells exhibited significantly increased cytotoxic activity against CD5-positive cell lines and primary tumor cells, compared to NK, CAR-NK92, and CAR-T cells. Moreover, CAR-NK cells effectively decreased the leukemic burden and extended survival in murine model. Additionally, an off-switch utilizing the HSV-TK switch system successfully eradicated CAR-NK cells for safety considerations.
Conclusions:
This study developed a controllable CD5 CAR-NK cells that exhibit high efficacy against T-cell malignancies, although further validation is necessary to assess their clinical potential.
Insights
Chimeric antigen receptor (CAR) Natural Killer (NK) cells targeting CD5 demonstrate potent anti-leukemia activity in preclinical models. A herpes simplex virus-1 thymidine kinase (HSV-TK) suicide switch ensures safety by enabling CAR-NK cell eradication.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- CAR T-cell therapy for T-cell malignancies is limited by fratricide due to shared CD5 antigen expression on normal and malignant T cells.
- Natural Killer (NK) cell immunotherapy presents a promising alternative for hematologic malignancies, but its efficacy requires further investigation.
Purpose of the Study:
- To develop and evaluate CD5-targeted chimeric antigen receptor (CAR) Natural Killer (NK) cells for T-cell malignancies.
- To assess the anti-tumor efficacy and safety of CAR-NK cells, including the implementation of a suicide switch system.
Main Methods:
- Generated CD5-targeted CAR-modified primary NK cells, T cells, and NK92 cell lines.
- Assessed anti-tumor efficacy using in vitro cytotoxicity assays and xenograft mouse models.
- Investigated the herpes simplex virus-1 thymidine kinase (HSV-TK) suicide switch system in CAR-NK cells with ganciclovir (GCV).
Main Results:
- CAR-NK cells showed significantly enhanced cytotoxic activity against CD5-positive cell lines and primary tumor cells compared to other cell types.
- CAR-NK cells effectively reduced leukemic burden and prolonged survival in a murine model.
- The HSV-TK suicide switch system successfully eradicated CAR-NK cells, confirming its safety application.
Conclusions:
- Developed controllable CD5 CAR-NK cells demonstrate high efficacy against T-cell malignancies.
- Further validation is required to ascertain the clinical potential of these CAR-NK cells for treating T-cell malignancies.
More Related Videos
08:29Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System
Published on: October 4, 2024
11:02Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
Published on: February 8, 2022
